Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oryzon Genomics S.A. (ORY.MC)
Cornellà de Llobregat, ES
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +3.84% | -2.29% | -11.79% | -8.93% | -9.52% | +8.23% | +36.60% | -18.67% | -2.63% | -38.83% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+38.5% ★ Q1'26: +40.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-7.2% ★ Q1'26: -18.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.5% Q1'26: +19.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.90× Q1'26: -0.52× (vs Q1'25)
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
735.3K
est: 4.84M (-84.8%)
|
16.8K
est: 4.74M (-99.6%)
|
—
est: 2.44M (-100.0%)
|
9.52M
est: 2.46M (+286.4%)
|
—
est: 12.88M (-100.0%)
|
—
est: 10.82M (-100.0%)
|
7.36M
est: 7.47M (-1.5%)
|
—
est: 12.61M (-100.0%)
|
7.30M
7.30M – 7.30M
-42.1% YoY
|
21.88M
21.88M – 21.88M
+199.7% YoY
|
166.05M
166.05M – 166.05M
+659.1% YoY
|
183.84M
183.84M – 183.84M
+10.7% YoY
|
295.72M
295.72M – 295.72M
+60.9% YoY
|
| EBITDA |
-3.69M
est: 302.1K (-1,321.5%)
|
-3.61M
est: 296.3K (-1,318.1%)
|
-3.70M
est: 152.8K (-2,519.6%)
|
-4.16M
est: 154.0K (-2,801.9%)
|
-5.35M
est: 804.8K (-764.8%)
|
-4.43M
est: 3.78M (-217.2%)
|
-4.43M
est: 2.61M (-269.6%)
|
-6.29M
est: 4.41M (-242.5%)
|
2.55M
2.55M – 2.55M
-42.1% YoY
|
7.65M
7.65M – 7.65M
+199.7% YoY
|
58.09M
58.09M – 58.09M
+659.1% YoY
|
64.32M
64.32M – 64.32M
+10.7% YoY
|
103.46M
103.46M – 103.46M
+60.9% YoY
|
| EBIT |
-4.54M
est: 256.1K (-1,874.2%)
|
-4.44M
est: 251.1K (-1,866.4%)
|
-3.83M
est: 129.5K (-3,061.2%)
|
-4.29M
est: 130.5K (-3,387.9%)
|
-5.50M
est: 682.1K (-905.8%)
|
-4.56M
est: 3.71M (-223.0%)
|
-4.58M
est: 2.56M (-278.7%)
|
-6.42M
est: 4.33M (-248.4%)
|
2.50M
2.50M – 2.50M
-42.1% YoY
|
7.51M
7.51M – 7.51M
+199.7% YoY
|
56.98M
56.98M – 56.98M
+659.1% YoY
|
63.08M
63.08M – 63.08M
+10.7% YoY
|
101.47M
101.47M – 101.47M
+60.9% YoY
|
| Net Income |
-5.45M
est: -10.30M (+47.1%)
|
-5.20M
est: -10.94M (+52.5%)
|
—
est: -7.64M (+100.0%)
|
-3.40M
est: -5.13M (+33.7%)
|
-4.23M
est: -4.52M (+6.3%)
|
-3.35M
est: -4.52M (+25.8%)
|
-3.67M
est: -3.53M (-3.7%)
|
-2.61M
est: -622.4K (-318.6%)
|
-8.68M
-8.68M – -8.68M
-1,294.0% YoY
|
-3.62M
-8.93M – 1.69M
+58.3% YoY
|
48.81M
32.54M – 65.09M
+1,449.8% YoY
|
123.19M
123.19M – 123.19M
+152.4% YoY
|
172.36M
172.36M – 172.36M
+39.9% YoY
|
| SGA |
2.47M
est: 4.56M (-45.8%)
|
2.01M
est: 4.47M (-55.1%)
|
3.34M
est: 2.31M (+45.0%)
|
9.68M
est: 2.32M (+316.4%)
|
17.62M
est: 12.15M (+45.0%)
|
3.61M
est: 10.17M (-64.5%)
|
3.45M
est: 7.02M (-50.9%)
|
-6.34M
est: 11.85M (-153.5%)
|
6.86M
6.86M – 6.86M
-42.1% YoY
|
20.56M
20.56M – 20.56M
+199.7% YoY
|
156.07M
156.07M – 156.07M
+659.1% YoY
|
172.80M
172.80M – 172.80M
+10.7% YoY
|
277.96M
277.96M – 277.96M
+60.9% YoY
|
| EPS |
-0.20
est: -0.16 (-25.0%)
|
-0.16
est: -0.17 (+5.9%)
|
—
est: -0.12 (+100.0%)
|
-0.06
est: -0.08 (+19.1%)
|
-0.08
est: -0.07 (-7.6%)
|
-0.06
est: -0.06 (+9.3%)
|
-0.06
est: -0.05 (-19.7%)
|
-0.04
est: -0.01 (-318.2%)
|
-0.12
-0.12 – -0.12
-1,294.0% YoY
|
-0.03
-0.12 – 0.02
+75.2% YoY
|
0.66
0.44 – 0.88
+2,365.8% YoY
|
1.66
1.66 – 1.66
+152.4% YoY
|
2.32
2.32 – 2.32
+39.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | 170.6K | 0.18% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 122.0K | 0.22% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 78.9K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carlos Manuel Buesa Arjol | Co-Founder, Chairman, Chief Executive Officer & President | 539.0K | — |
| Emili Torrell Cortada | Director of Business Development | — | male |
| Enric Rello Condomines | Chief Operating Officer & Chief Financial Officer | — | male |
| Jordi Xaus Pey | Scientific Director | — | male |
| Neus Virgili Bernado | Director of Industrial Property | — | female |
| Rolando Gutierrez-Esteinou | Chief Medical Officer for CNS Programs | — | — |
| Sonia Paloma Gutierrez Bezon | Director of Clinical Operations | — | female |
| Augusto Pinel Rubio | Secretary | — | male |
| Xavier Perpinya Ribera | Head of Internal Audit & Compliance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORY.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
